This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Serology in COVID-19 – Comparison of Two Methods
Anna Moniuszko-Malinowska
Medical University of Białystok
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The aim of our study was to investigate the difference in the anti-SARS-CoV-2 antibodies assessment with two various assays. 127 patients exposed to SARS-CoV-2 were included. Two serological tests were used: SARS-CoV-2 IgG CMIA on the Alinity system (ABBOTT) and LIAISON® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin). Both assays exhibited 96.85% (123/127 patients) overall compatibility. In 2 cases the positive results in N-based test, were negative in S-based test, and in 2 cases negative results in S-based test were positive in N-based test. Based on the results of our study we concluded that the assessment of anti-SARS-CoV-2 antibodies against N and S protein in population medicine shows comparable usefulness of both tests.
Keywords
SARS-CoV-2, chemiluminescent immunoassay, serology, spike protein, nucleocapsid protein
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 23 Dec, 2020
No community comments so far
Reviewers invited
Invitations sent on 01 Jan, 2021
Editor assigned
On 29 Dec, 2020
Editor invited
On 22 Dec, 2020
Submission checks complete
On 22 Dec, 2020
First submitted
On 05 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Serology in COVID-19 – Comparison of Two Methods
Anna Moniuszko-Malinowska
Medical University of Białystok
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 23 Dec, 2020
No community comments so far
Reviewers invited
Invitations sent on 01 Jan, 2021
Editor assigned
On 29 Dec, 2020
Editor invited
On 22 Dec, 2020
Submission checks complete
On 22 Dec, 2020
First submitted
On 05 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The aim of our study was to investigate the difference in the anti-SARS-CoV-2 antibodies assessment with two various assays. 127 patients exposed to SARS-CoV-2 were included. Two serological tests were used: SARS-CoV-2 IgG CMIA on the Alinity system (ABBOTT) and LIAISON® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin). Both assays exhibited 96.85% (123/127 patients) overall compatibility. In 2 cases the positive results in N-based test, were negative in S-based test, and in 2 cases negative results in S-based test were positive in N-based test. Based on the results of our study we concluded that the assessment of anti-SARS-CoV-2 antibodies against N and S protein in population medicine shows comparable usefulness of both tests.